| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | SELL | SELL | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 1.66▲ | 1.66▲ | 1.67▼ | 1.69▼ | 1.91▼ |
| MA10 | 1.66▲ | 1.67▼ | 1.66▲ | 1.89▼ | 1.89▼ |
| MA20 | 1.66▲ | 1.67▼ | 1.64▲ | 1.97▼ | 1.89▼ |
| MA50 | 1.67▼ | 1.66▲ | 1.74▼ | 1.87▼ | 2.93▼ |
| MA100 | 1.67▼ | 1.78▼ | 1.93▼ | 1.90▼ | 7.10▼ |
| MA200 | 1.65▲ | 1.93▼ | 1.94▼ | 2.37▼ | 10.13▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.001▲ | -0.001▼ | 0.012▲ | -0.060▼ | 0.118▲ |
| RSI | 53.237▲ | 50.303▲ | 46.832▼ | 42.082▼ | 39.581▼ |
| STOCH | 75.000 | 36.097 | 62.407 | 5.128▼ | 58.714 |
| WILL %R | 0.000▲ | -57.143 | -34.783 | -93.349▼ | -88.926▼ |
| CCI | 120.000▲ | -56.140 | 28.205 | -80.247 | -97.245 |
|
Monday, October 13, 2025 08:24 AM
Biomea Fusion’s stock fell 33.9% after announcing a $25M public offering, raising investor concerns over dilution despite promising diabetes trial results.
|
|
Tuesday, October 07, 2025 07:35 AM
Biomea Fusion reported favorable safety for icovamenib in a 52-week diabetes study, alongside a $25 million public offering.
|
|
Tuesday, October 07, 2025 05:20 AM
All of the shares, pre-funded warrants and accompanying common stock warrants in the offering are being sold by Biomea. The gross proceeds to Biomea from the offering, before deducting underwriting ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 15/10/25 | 1.685 | 1.705 | 1.635 | 1.665 | 1,116,097 |
| 14/10/25 | 1.63 | 1.68 | 1.5706 | 1.67 | 1,642,385 |
| 13/10/25 | 1.69 | 1.7143 | 1.60 | 1.65 | 1,952,677 |
| 10/10/25 | 1.78 | 1.78 | 1.65 | 1.68 | 3,258,129 |
| 09/10/25 | 1.70 | 1.79 | 1.66 | 1.79 | 3,356,692 |
| 08/10/25 | 1.87 | 1.89 | 1.67 | 1.68 | 6,974,648 |
| 07/10/25 | 1.98 | 2.01 | 1.66 | 1.845 | 21,514,954 |
| 06/10/25 | 2.17 | 2.99 | 2.15 | 2.67 | 14,446,822 |
| 03/10/25 | 2.15 | 2.23 | 2.13 | 2.15 | 404,163 |
| 02/10/25 | 2.11 | 2.14 | 2.03 | 2.13 | 417,052 |
|
|
||||
|
|
||||
|
|